Disease · MONDO_0002729

rhabdoid tumor of the kidney

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. rhabdoid tumor of the kidney. Diseases, record MONDO_0002729. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002729

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: rhabdoid tumor of the kidney; Open Targets
Open Targets ID: MONDO_0002729; Open Targets
Other names: MRTK, kidney rhabdoid tumor, kidney rhabdoid tumour, malignant rhabdoid tumor of kidney, malignant rhabdoid tumor of the kidney, malignant rhabdoid tumour of kidney, malignant rhabdoid tumour of the kidney, renal rhabdoid neoplasm, renal rhabdoid tumor, renal rhabdoid tumour, rhabdoid neoplasm of kidney, rhabdoid neoplasm of the kidney, rhabdoid tumor of kidney, rhabdoid tumor of the kidney (RTK), rhabdoid tumour of kidney, rhabdoid tumour of the kidney, rhabdoid tumour of the kidney (RTK); Open Targets
Disease Ontology: DOID:3674; Disease Ontology
NCI Thesaurus: C8715; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DACTINOMYCIN	CHEMBL1554	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE SULFATE	CHEMBL501867	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TAZEMETOSTAT	CHEMBL3414621	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	3	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02601950	A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma	Phase 2	267	2025-03-11	Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation	DOXORUBICIN, TAZEMETOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02601937	EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	Phase 1	109	2024-10-03	Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary	TAZEMETOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00002611	Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer	Phase 3	3,031		Kidney Cancer	CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01285817	A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.	Phase 2	79		Survival Without Progression	CELECOXIB, CYCLOPHOSPHAMIDE, METHOTREXATE, VINBLASTINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22952427	RESULT	1	PubMed
21189373	RESULT	1	PubMed
19208794	RESULT	1	PubMed
18989885	RESULT	1	PubMed
17539021	RESULT	1	PubMed
16710034	RESULT	1	PubMed
16410127	RESULT	1	PubMed
16172460	RESULT	1	PubMed
16129848	RESULT	1	PubMed
15868587	RESULT	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002729

GET https://conductscience.org/api/diseases/v1/MONDO_0002729/targets?page=2

API reference For AI assistants